All In Biotech

NDA 019516 · Knoa Pharma

Ms Contin

Morphine Sulfate · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

May 29, 1987

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,053

400 Phase 3, 129 recruiting

FAERS reports

121,251

103,850 serious, 35,051 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MS CONTIN Addiction, Abuse, and Misuse Because the use of MS CONTIN exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warning and Precautions (5.1) ]. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of MS CONTIN, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of MS CONTIN are essential. Instruct patients to swallow MS CONTIN tablets whole; crushing, chewing, or dissolving MS CONTIN tablets can cause rapid release and absorption of a potentially fatal dose of...

What it is approved for

From the label in effect Aug 14, 2026.

MS CONTIN is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.2) ] , reserve opioid analgesics, including MS CONTIN, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. MS CONTIN is not indicated as an as-needed (prn) analgesic. MS CONTIN is an opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including MS CONTIN, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) MS CONTIN is not indicated as an as-needed (prn) analgesic. ( 1 )

Mechanism: Morphine is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 29, 1987 Original approval · Type 3 - New Dosage Form · priority review Other
5 products under this application
  • MS CONTIN · MORPHINE SULFATE 200MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
  • MS CONTIN · MORPHINE SULFATE 15MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • MS CONTIN · MORPHINE SULFATE 30MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • MS CONTIN · MORPHINE SULFATE 100MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
  • MS CONTIN · MORPHINE SULFATE 60MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Morphine" as an intervention, any sponsor and status, largest first.

All 2,053 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence32,898
  • overdose23,556
  • pain21,727
  • death17,487
  • emotional distress16,960
  • drug withdrawal syndrome13,755
  • toxicity to various agents11,853
  • drug hypersensitivity10,283
  • nausea5,733
  • dependence5,010
  • drug ineffective4,972
  • fatigue4,059

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,656
20051,527
20061,241
2007791
2008884
2009959
20101,280
20111,568
20122,361
20131,882
20142,318
20153,026
20163,584
20174,918
201826,849
20194,813
20208,668
202120,582
202214,405
20238,462
20243,692
20253,483
20262,297

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ms Contin (Morphine Sulfate)

2024 spending

$716K

Beneficiaries

224

1,013 claims

Per beneficiary

$3,197

$8.01 per unit

View as table
YearSpending
2020$1,922,907
2021$1,651,076
2022$1,320,832
2023$1,079,068
2024$716,132

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8,879 on PubMed

Sponsor: Knoa Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.